Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (MM)
Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (MM)
The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS).
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Inclusion Criteria:
Documented progression from most recent line of therapy
1-3 prior lines of therapy
Measurable disease
Life expectancy ≥3 months
Prior treatment with Lenalidomide permitted if:
Exclusion Criteria:
Canberra, New South Wales 2605, Australia
Brussles, 1200, Belgium
Edegem-antwerp, 2650, Belgium
Pierre Benita, 69495, France
Shibukawa-shi, Gunma 3770280, Japan
Bunkyo-Ku, Tokyo 1138677, Japan
Koto-ku, Tokyo 1358550, Japan
Shibuya-ku, Tokyo 1508935, Japan
Shinjuuku-ku, Tokyo 1608582, Japan
Bucaresti, 030171, Romania
Badalona-Barcelona, 08916, Spain
Santiago de Comp-coruna, 15706, Spain
Leicester, LE1 5WW, United Arab Emirates